Date Title Description PDF
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
26 Feb 2020 Annual Corporate Governance Report ROVI releases the 2019 Annual Corporate Governance Report Download
26 Feb 2020 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2019 annual report regarding remuneration of the members of the Board of Directors  Download

Pages

Date Title Description PDF
05 Jul 2019 R&D: new licenses, patents and registered trademarks ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. Download
02 Jul 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the second quarter of 2019 Download
26 Jun 2019 Información sobre dividendos The Company informs about the dividends payment Download
12 Jun 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its General Shareholders Meeting Download
08 May 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its 2019 General Shareholders Meeting Download

Pages